文献速递妇科

妇科肿瘤临床试验中的人口统计学报告与语言排除

Demographic reporting and language exclusion in gynecologic oncology clinical trials.
PubMed 文献 · Am J Obstet Gynecol · 2023-09-24

该研究检索1997至2021年ClinicalTrials.gov上的妇科肿瘤研究,评估入排标准中的人口学筛选及已发表研究中人口学变量的报告情况。共纳入1597项研究,12%因语言排除患者,已发表的581项研究中63%报告种族、29%报告民族。宫颈癌试验中白人患者占37%,低于子宫癌的85%和卵巢癌的82%。

要点

  • 12%的妇科肿瘤试验因语言排除患者,行业资助试验较研究者发起试验更少因语言排除。
  • 已发表研究中95%报告年龄、63%报告种族、29%报告民族,宫颈癌研究报告人口学信息最多。
  • 宫颈癌试验白人患者占37%,子宫癌85%,卵巢癌82%,少数族裔代表性不足。

核心结论

  • 过去30年,十分之一的妇科肿瘤试验因语言排除患者,种族和民族在超过一半的可用研究中被报告,亟需提高招募代表性不足患者和报告人口学数据的透明度。

研究设计与样本

  • 检索ClinicalTrials.gov上1997至2021年开展的妇科肿瘤研究,共纳入1597项,其中已发表581项,审查入排标准中的人口学筛选因素并识别已发表研究报告的人口学变量。

主要发现

  • 1597项研究中,卵巢癌883项(55%)、宫颈癌336项(21%)、子宫癌262项(17%)、多部位妇科肿瘤116项(7%)。
  • 已发表581项研究中,554项(95%)报告年龄,363项(63%)报告种族,171项(29%)报告民族。
  • 宫颈癌研究最可能报告人口学信息,包括种族(P=.026)和民族(P<.001)。
  • 189项研究(12%)基于语言排除患者;行业资助试验较研究者发起试验更少因语言排除(OR 0.07,95%CI 0.02-0.30),组织资助试验亦更少(OR 0.40,95%CI 0.22-0.73)。
  • 宫颈癌试验中白人患者占37%,子宫癌试验占85%,卵巢癌试验占82%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Participation in clinical trials may help mitigate disparate cancer outcomes. Thus, ensuring equitable access to clinical trials is a major priority for national cancer organizations. OBJECTIVE: This study aimed to examine clinical trial eligibility criteria that may adversely affect the enrollment of underrepresented groups and assess the availability of demographic information in published gynecologic oncology studies. STUDY DESIGN: ClinicalTrials.gov was searched for gynecologic oncology studies conducted between 1997 and 2021. Each study's inclusion and exclusion criteria were reviewed to determine whether demographic factors were used for enrollment screening. For published studies, demographic variables that were reported were identified. The expected clinical trial enrollment based on disease incidence and mortality was compared with the observed trial enrollment based on race. RESULTS: There were 1597 gynecologic oncology studies: 883 (55%) from ovarian cancer studies, 336 (21%) from cervical cancer studies, 262 (17%) from uterine cancer studies, and 116 (7%) from multisite gynecologic oncology studies. Of the 581 published studies, 554 (95%) reported age, 363 (63%) reported race, and 171 (29%) reported ethnicities. Cervical cancer studies were most likely to report demographic information, including race (P=.026) and ethnicity (P<.001). During the study period, 189 studies (12%) excluded patients based on the language spoken. Industry-sponsored trials (odds ratio, 0.07; 95% confidence interval, 0.02-0.30) and organization-sponsored trials (odds ratio, 0.40; 95% confidence interval, 0.22-0.73) were less likely to exclude patients because of language than investigator-initiated trials. A minority of patients (37%) in cervical cancer trials were of White race, compared with 85% of patients in uterine cancer trials and 82% of patients in ovarian cancer trials. CONCLUSION: Over the last 3 decades, 1 in 10 gynecologic oncology trials excluded patients because of language. Race and ethnicity were reported in more than half of the available studies. Initiatives to increase transparency in recruiting underrepresented patients and reporting demographic data are urgently needed.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lee SS, Dinicu AI, Arthurs L, et al. Demographic reporting and language exclusion in gynecologic oncology clinical trials. Am J Obstet Gynecol. 2023. PMID: 37751830. doi:10.1016/j.ajog.2023.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。